The Medical Letter on Drugs and Therapeutics
Ocriplasmin (Jetrea) for Vitreomacular Adhesion
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Ocriplasmin (Jetrea – ThromboGenics) was recently approved by the FDA as an intravitreal injection for treatment of symptomatic vitreomacular adhesion. It is the first drug to be approved in the US for this indication.

VITREOMACULAR ADHESION — As part of the normal aging process, the gel-like vitreous begins to liquefy and can start to separate from the retina. If the vitreous detaches from most of the retina but not the macula (vitreomacular adhesion), vitreomacular traction can occur, possibly resulting in retinal distortion, macular edema and macular hole formation. Symptoms include photopsia (flashes of light) and distorted or reduced vision. The standard treatment for progressive disease is surgical vitrectomy, which can be complicated by infection, bleeding, cataract formation, and retinal tears or detachment.1

MECHANISM OF ACTION — Ocriplasmin is ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ocriplasmin (Jetrea) for Vitreomacular Adhesion
Article code: 1422c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian